Following previous studies in rheumatoid arthritis, SynAct Pharma knows much more about the possibilies and requirements for assessing resomelagon's effect. The company is now acting on its strategy by initiating the filing process for a new clinical phase IIb study with resomelagon in patients with severe, newly diagnosed RA with signs of systemic inflammation. BioStock reached out to CEO Jeppe Øvlesen to learn more about the clinical trial, named ADVANCE.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/07/synact-pharma-moves-forward-with-filing-process/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/synact/r/biostock-synact-pharma-moves-forward-with-filing-process,c4011216

(c) 2024 Cision. All rights reserved., source Press Releases - English